Codexis Return on Assets:
-29.20% for Dec. 31, 2012Codexis Historical Return on Assets Data
Pro Data Export
Dates:
to
There is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| March 31, 2013 | -29.20% |
| Dec. 31, 2012 | -25.41% |
| Sept. 30, 2012 | -15.81% |
| June 30, 2012 | -15.73% |
| March 31, 2012 | -14.78% |
| Dec. 31, 2011 | -11.78% |
| Sept. 30, 2011 | -8.22% |
| June 30, 2011 | -8.22% |
| March 31, 2011 | -8.05% |
| Dec. 31, 2010 | -6.93% |
| Sept. 30, 2010 | -11.65% |
About Return on Assets
Return on Assets (ROA) shows the rate of return (after tax) being earned on all of the firm's assets regardless of financing structure (debt vs. equity). It is a measure of how efficiently the company is using all stakeholders' assets to earn returns.
Because ROA can differ significantly across firms, ROA is often used to compare a company over time or against companies that have similar financing structures.
Learn More
CDXS Return on Assets Benchmarks
| Companies | |
|---|---|
| Albany Molecular Research | -1.43% |
| Corcept Therapeutics | -58.35% |
| Exelixis | -27.71% |
CDXS Return on Assets Rankings
| Overall |
44th percentile 4417 of 8005 |
| Sector |
47th percentile 360 of 686 in Healthcare |
| Industry |
69th percentile 76 of 248 in Biotechnology |
CDXS Return on Assets Range, Past 5 Years
| Minimum | -29.20% | Mar 2013 |
| Maximum | -6.93% | Dec 2010 |
| Average | -14.16% |
